Cargando…

AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations

Tumor suppressor p53 is responsible for enforcing cell cycle checkpoints at G1/S and G2/M in response to DNA damage, thereby allowing both normal and tumor cells to repair DNA before entering S and M. However, tumor cells with absent or mutated p53 are able to activate alternative signaling pathways...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Xiangbing, Bi, Jianling, Li, Yujun, Yang, Shujie, Zhang, Yuping, Li, Mary, Liu, Haitao, Li, Yiyang, Mcdonald, Megan E., Thiel, Kristina W., Wen, Kuo-Kuang, Wang, Xinhao, Wu, Meng, Leslie, Kimberly K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977122/ https://www.ncbi.nlm.nih.gov/pubmed/29783721 http://dx.doi.org/10.3390/cancers10050149

Ejemplares similares

Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations
por: Meng, Xiangbing, et al.
Publicado: (2018)

Role of metadherin in estrogen-regulated gene expression
por: Li, Yujun, et al.
Publicado: (2017)

Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint
por: Lin, Xiaoting, et al.
Publicado: (2018)

Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53
por: Meng, Xiangbing, et al.
Publicado: (2013)

Inhibiting the IRE1α Axis of the Unfolded Protein Response Enhances the Antitumor Effect of AZD1775 in TP53 Mutant Ovarian Cancer
por: Xiao, Rourou, et al.
Publicado: (2022)

Knockdown of MTDH Sensitizes Endometrial Cancer Cells to Cell Death Induction by Death Receptor Ligand TRAIL and HDAC Inhibitor LBH589 Co-Treatment
por: Meng, Xiangbing, et al.
Publicado: (2011)

Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
por: Någård, Mats, et al.
Publicado: (2020)

AZD1775 induces toxicity through double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal cancer cells
por: Webster, Peter John, et al.
Publicado: (2017)

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2017)

Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations
por: Serpico, Angela Flavia, et al.
Publicado: (2019)

AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair
por: Ford, James B., et al.
Publicado: (2015)

Wee1 Inhibitor AZD1775 Effectively Inhibits the Malignant Phenotypes of Esophageal Squamous Cell Carcinoma In Vitro and In Vivo
por: Bi, Shuning, et al.
Publicado: (2019)

Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study
por: Någård, Mats, et al.
Publicado: (2023)

Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas
por: Kreahling, Jenny M., et al.
Publicado: (2013)

Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis
por: Chen, Dongshao, et al.
Publicado: (2018)

Utilizing an Endogenous Progesterone Receptor Reporter Gene for Drug Screening and Mechanistic Study in Endometrial Cancer
por: Li, Yiyang, et al.
Publicado: (2022)

Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring
por: Seligmann, Jenny F., et al.
Publicado: (2021)

Inverse Relationship between Progesterone Receptor and Myc in Endometrial Cancer
por: Kavlashvili, Tamar, et al.
Publicado: (2016)

A Mechanism for Synergy with Combined mTOR and PI3 Kinase Inhibitors
por: Yang, Shujie, et al.
Publicado: (2011)

Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations
por: Meng, Xiangbing, et al.
Publicado: (2021)

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
por: Fok, Jacqueline H. L., et al.
Publicado: (2019)

WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells
por: Moiseeva, Tatiana N., et al.
Publicado: (2019)

Mathias Mayor (1775–1847)
por: Librach, I. M.
Publicado: (1970)

Medicine in Charlestown in 1750-1775
por: Waring, Joseph Ioor
Publicado: (1935)

ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
por: Wilson, Zena, et al.
Publicado: (2022)

Metadherin enhances vulnerability of cancer cells to ferroptosis
por: Bi, Jianling, et al.
Publicado: (2019)

Fundación Piadosa en Veracurz 1775
por: Gil, Francisco
Publicado: (1964)

Health Education From 1775 to 2005
por: Wilcox, Lynne S.
Publicado: (2005)

The Army Medical Department 1775–1818
por: Watt, Sir James
Publicado: (1982)

The Doctor in French Drama, 1700-1775
por: Smith, Geo. H.
Publicado: (1938)

A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations
por: Zhou, Liang, et al.
Publicado: (2014)

Augmentation of the therapeutic efficacy of WEE1 kinase inhibitor AZD1775 by inhibiting the YAP–E2F1–DNA damage response pathway axis
por: Oku, Yusuke, et al.
Publicado: (2018)

Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine
por: Isono, Makoto, et al.
Publicado: (2017)

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
por: Khan, O A, et al.
Publicado: (2011)

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells
por: Arun, Banu, et al.
Publicado: (2015)

OR04-6 Comprehensive Profiling of the MELK Inhibitor OTSSP167's Action and Its Effect on Sensitization to Wee1 Inhibitor AZD1775 in a Spectrum of ACC Models
por: Bagby, Stacey, et al.
Publicado: (2022)

A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors
por: Bauer, Todd M., et al.
Publicado: (2023)

Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors
por: Någård, Mats, et al.
Publicado: (2023)

Henry Marshall (1775-1851) and the health of the British Army.
por: Blanco, R L
Publicado: (1970)

The letters and papers of Sir John Hill, 1714–1775
por: Porter, Roy
Publicado: (1983)

Cannot write session to /tmp/vufind_sessions/sess_4vvrge60v8qu6gs7er7e1k6oe6